E.A. PAVLOVSKAYA, A.G. AVTANDILOV, M.S. BULGAKOV

Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation, 2 Barrikadnaya Str., Moscow,  Russian Federation, 123242

Pavlovskaya E.A. — Cand. Med. Sc., assistant of the Department of Therapy and Adolescent Medicine, e-mail: zhenyaermakova@gmail.com

Avtandilov A.G. — D. Med. Sc., Professor, Head of the Departament of Therapy and Adolescent Medicine, e-mail:algav@mail.ru

Bulgakov M.S. — Cand. Med. Sc., Department of Therapy and Adolescent Medicine, e-mail: Mikhail.Bulgakov@bionorica.ru

The aim of the study was to evaluate the clinical possibilities and effectiveness of the use of metabolic cytoprotectors in patients with paroxysmal atrial fibrillation and ischemic heart disease. The study included 65 patients who were divided into 3 groups depending on the frequency and duration of AF paroxysms. In group 1, patients received amiodaric and trimetazidine, in group 2 only trimetazidine and in 3 only amiodarone. Data have been obtained that complex antiarrhythmic therapy of the paroxysmal form of AF leads to a reduction in the number of paroxysms and their duration, and also leads to a decrease in the duration of the QT interval, which is most pronounced in patients with an initially prolonged QT interval

Key words: atrial fibrillation, QT interval, trimetazidine.